Home - TG Therapeutics
WEBlatest news New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92
WEB4 days ago · NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and ...
TG Therapeutics Announces FDA Approval of BRIUMVI™ …
WEBNEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and …
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB3 days ago · Sep. 18, 2024, 08:24 AM. (RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The ...
TG Therapeutics - New BRIUMVI Data from the ENHANCE Phase …
WEB2 days ago · NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated ...
TG Therapeutics Stock Surges After Preventing MS Relapses Over …
WEB3 days ago · Related news TG Therapeutics Receives Composite Rating Upgrade. 9/09/2024 TG Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 97.. 9/09/2024 TG ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB3 days ago · TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data showed rapid 30 minute infusions were well tolerated. Data also showed that patients switching from prior anti-CD20 treatment can …
TG Therapeutics, Inc. - MarketScreener.com
WEB3 days ago · TG Therapeutics, Inc. announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, where the company and their partner in Europe, Neuraxpharm ...
Are Robust Financials Driving The Recent Rally In TG Therapeutics…
WEB2 days ago · So, based on the above formula, the ROE for TG Therapeutics is: 54% = US$96m ÷ US$178m (Based on the trailing twelve months to June 2024). The 'return' is the yearly profit.
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase …
WEB4 days ago · TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI ...
Skip to content